A Study of the Safety, Tolerability and Preliminary Efficacy of B2065 in Patients With Acute Ischemic Stroke.

NCT07371624 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Ischemic Stroke

Interventions

DRUG: B2065
DRUG: Placebo

Sponsor

Tasly Pharmaceutical Group Co., Ltd